Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Merck KGaA    MRK   DE0006599905

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Merck KGaA Gives Details On Planned Efficiency Program

share with twitter share with LinkedIn share with facebook
share via e-mail
02/24/2012 | 05:51pm CET

-- Germany's Merck provides details about efficiency program.

-- Conglomerate joins a long list of drug makers revamping themselves.

-- Merck KGaA shares fall after restructuring update.

(Adds details, share details, background.)

   By Neetha Mahadevan 

Pharmaceutical and chemical company Merck KGaA (>> Merck KGaA) said Friday it launched a cost-cutting and efficiency plan in the wake of increased price pressures in the U.S. and Europe and a series of drug development setbacks.

The company said the plan could involve job cuts across all businesses and regions to reduce costs and address "unprecedented market shifts", but it didn't disclose details, saying management still needed to speak with relevant stakeholders for a mutually acceptable solution.

"Over the next two years, Merck needs to address unprecedented market shifts, increasing competition in key product areas and existing inefficiencies in its own organization to ensure the long-term success of its business model," Chief Executive Karl-Ludwig Kley said in a statement.

With its new cost-cutting drive, the German chemical and pharmaceutical company joins a long list of other drug makers who are revamping themselves in response to falling sales and profitability.

The need to cut costs is partly due to mounting pressure stemming from health care reforms in the U.S. and Europe, where governments are increasingly reluctant to reimburse expensive drugs and advocate the use of cheaper generic medicines. Companies such as AstraZeneca Plc (AZ.LN), Novartis AG (NVS), Roche Holding AG (ROG.VX), Pfizer Inc (>> Pfizer Inc.), Eli Lilly & Co (>> Eli Lilly & Co.) have all embarked on cost saving or restructuring programs to keep costs under control.

In addition to set-backs in its drug pipeline, Merck has also been hit by a slowdown in demand at its chemicals division, which led to disappointing developments in the last year and prompted it to tighten its outlook time and again.

In the second-quarter, it recorded a 6.5% drop in revenue at its chemicals division, while in the third-quarter profits fell due largely to weakness in its performance materials division.

The efficiency measures are part of Merck's comprehensive transformation program, announced last year, and comprises two phases, the company said.

In the first two years, Merck plans to set up a new leadership organization, implement efficiency measures and focus on long-term growth, while the second phase will be focused on exploiting new growth opportunities, it added.

Merck KGaA shares fell after the news and at 1545 GMT traded down 1.2% at EUR79.70, while the DAX benchmark index traded 0.6% higher.

-By Neetha Mahadevan, Dow Jones Newswires; +49 69 2972 5507; [email protected]

(Sten Stovall contributed to this article.)

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK KGAA
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/14 Perrigo lines up bid for Merck's consumer health unit - sources
12/13 MERCK : New Partnership to Fight Schistosomiasis in Ethiopia
12/12DJMERCK : Appoints Allan Gabor as Managing Director in China
12/12 MERCK : Allan Gabor Takes Over the Leadership of Merck KGaA, Darmstadt, Germany,..
12/11 REGENEUS LTD (ASX : RGS) Appoints Japan-Based Non-Executive Director with Extens..
12/11 MERCK : EMD Serono - John Walsh, M.D. Joins EMD Serono as Vice President of Neur..
12/11 MERCK : MilliporeSigma Signs Distribution Agreement with Avanti® Polar Lipids
12/10 REGENEUS LTD (ASX : RGS) Appoints Japan-Based Non-Executive Director with Extens..
12/07 MERCK : Darmstadt, Germany Receives Approval (Updated Registration) for Cladribi..
More news
News from SeekingAlpha
12/14 Perrigo to bid for German Merck's consumer health unit - Reuters
12/04 Merck KGaA's Mavenclad OK'd in Canada
12/01 Suitors preparing bids for Merck KgaA's consumer health unit
11/20 Roche Rocks On With More Good News
11/13 Orexigen Contrave up 10% on Contrave distribution deal with Merck KGaA for La..
Financials (€)
Sales 2017 15 341 M
EBIT 2017 3 325 M
Net income 2017 1 658 M
Debt 2017 9 825 M
Yield 2017 1,40%
P/E ratio 2017 20,37
P/E ratio 2018 20,44
EV / Sales 2017 1,40x
EV / Sales 2018 1,25x
Capitalization 11 638 M
Duration : Period :
Merck KGaA Technical Analysis Chart | MRK | DE0006599905 | 4-Traders
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 108 €
Spread / Average Target 20%
EPS Revisions
Wolfgang Heinz Büchele Chairman-Supervisory Board
Marcus Kuhnert Chief Financial Officer
Crocifissa Attardo Member-Supervisory Board
Mechthild Auge Member-Supervisory Board
Michael Fletterich Vice Chairman-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA-9.18%13 715
ABBVIE55.46%153 511
CONVATEC GROUP-13.13%5 322